$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cidara Therapeutics, Inc. (NASDAQ: CDTX)

Core Viewpoint - Monteverde & Associates PC is investigating the proposed sale of Cidara Therapeutics, Inc. to Merck Sharp & Dohme LLC, where Cidara shareholders are set to receive $221.50 per share in cash, raising questions about the fairness of the deal [1]. Group 1: Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders [1]. - The firm is located in the Empire State Building, New York City, and specializes in class action securities litigation [2]. Group 2: Transaction Details - Cidara Therapeutics, Inc. shareholders will receive $221.50 per share in cash as part of the proposed transaction with Merck Sharp & Dohme LLC [1].